TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) is a Frederick, Maryland-based provider of disinfection and decontamination systems built on its Binary Ionization Technology platform and sold under the SteraMist brand to hospitals, life-science laboratories, food processors and government facilities. The stock was quoted at $2.15 shortly after midday, down 9.66% from the previous session's close of $2.38, a decline of $0.23. Direction was unambiguously negative: shares opened at $2.35, beneath the prior close, slipped to $2.10 and never traded higher on the day. No verified news catalyst explained the drop.
No verified news or fundamental catalyst found in the company's disclosure record, news wires or analyst commentary explains today's decline. The most recent material items — preliminary third-quarter results published Nov. 12 showing revenue of $2.49 million, up 24% year over year, operating income of roughly $30,000 and a commercial pipeline near $35 million, plus confirmation on Nov. 17 that Nasdaq minimum bid price and stockholders' equity requirements had been regained — were all published before the current session and were followed by gains, not selling.
The decline is therefore best assessed as profit-taking inside an extended, low-float advance, consistent with the stock's recent behavior. Even after today's slide, TOMZ remains up roughly 50% over the past month, and sellers have repeatedly emerged above the $2.35–$2.40 band that has capped rallies since the mid-November peak. A second, slower-moving overhang is structural: the company has not yet filed its quarterly report for the September quarter pending a review of convertible-note accounting, and management has said working capital remains a constraint, with additional financing among the options under discussion. In a name that trades a few tens of thousands of shares a day, that combination of a stretched chart and a pending filing is sufficient to produce outsized downside on modest order flow.
Turnover was light rather than panicked. Only about 9,500 shares had changed hands by late morning against a daily average near 37,000, indicating limited institutional participation and a thin order book rather than distribution on heavy volume. That pattern fits a liquidity-driven reversal more than a fundamental re-rating.
The move was also idiosyncratic. Nothing in the macro calendar or the broader healthcare and industrial equipment complex appeared large enough to justify a near-10% single-stock decline, and the shares remain far below their 52-week high of $3.24 but well above the 52-week low of $1.21. Technically, the stock failed at $2.35 on the open and broke back below the area that supported the early-November breakout, keeping the short-term trend corrective while the longer uptrend off the September low stays intact. Market capitalization sits near $21 million on roughly 10 million shares outstanding.
The score runs from 0, meaning no meaningful news and a move that is entirely normal for the stock, to 100, meaning transformative news combined with an extreme, rare price move. This event scores 13 out of 100. No verified news was published before the decline, so the fundamental component is minimal; the constructive items from the prior week were already reflected in the share price. The price component is also modest: the 9.66% drop was about 2.2 times the stock's typical absolute daily move of roughly 4.4% over the past 60 sessions, and seven of those sessions produced equal or larger swings. Two weak components combine into a low score.
The immediate item is the delayed Form 10-Q. Until the convertible-note review closes, net loss per share and equity balances remain subject to revision, and the resolution will either clear the overhang or revive questions about disclosure timing. Nasdaq's continued listing grant carries conditions that investors should track in subsequent filings.
Commercially, attention shifts to the roughly $5 million of purchase orders management expects to receive before year-end and to progress on food-safety registrations, including the FDA pre-notification consultation and international pathways with Nestlé and Danone. Those approvals, not order announcements, are the gate to the larger pipeline. The company's $12 million revenue goal for 2026 requires a strong fourth quarter, and fourth-quarter and full-year results are expected in the first quarter of calendar 2027. Risks include reliance on a narrow product line, working capital constraints, possible dilution from financing, and the volatility inherent to a micro-cap with a limited float.
Tickeron's Trending AI Robots page curates the automated strategies performing best under present market conditions, drawn from a library of hundreds of AI trading bots that cover thousands of tickers. Bots differ widely by strategy logic, holding period, performance metrics and the symbols they trade, so the featured list changes as market conditions shift. It is a practical starting point for investors comparing systematic approaches against their own research. Review the current leaders and see how each bot's parameters line up with your objectives.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 10-day RSI Indicator for TOMZ moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In 27 of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 53 cases where TOMZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on November 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TOMZ as a result. In 77 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TOMZ turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TOMZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TOMZ broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
TOMZ moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TOMZ crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +22.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where TOMZ advanced for three days, in 175 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 97 of 117 cases where TOMZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TOMZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.229) is normal, around the industry mean (10.189). P/E Ratio (-4.125) is within average values for comparable stocks, (-16.372). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (0.975). Dividend Yield (0.000) settles around the average of (0.050) among similar stocks. P/S Ratio (1.637) is also within normal values, averaging (251.106).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TOMZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry IndustrialSpecialties